Pancreatic Cancer Market
Market Insights on Pancreatic Cancer sales outlook, demand forecast & up-to-date key trends
Pancreatic Cancer Market by Treatment Type, Cancer Type, End User & Region – Forecast 2023–2033
Pancreatic Cancer Market Snapshot (2023-2033)
The global pancreatic cancer market will be valued at around US$ 2,125.57 Million in 2023. Market of Pancreatic Cancer are projected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033.
Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role.
|
Data Points |
Key Statistics |
|
Anticipated Base Year Value (2022) |
US$ 1,872.75 Million |
|
Expected Market Value (2023) |
US$ 2,125.57 Million |
|
Projected Forecast Value (2033) |
US$ 7,541.09 Million |
|
Global Growth Rate (2023-2033) |
13.5% CAGR |
|
Expected Market Share of the U.S. Market (2033) |
53% |
|
Anticipated Market Value of Europe (2023-2033) |
31% |
Let us know your requirement to get
100% FREE customization
Revenue Analysis of Pancreatic Cancer from 2018-2022 Vs Market Projections for 2023 to 2033
Despite advances in surgical technique, chemotherapy treatments, and the emergence of neoadjuvant chemoradiotherapy, five-year survivorship from this ailment is as low as 2.5% in certain countries. The total number of reported cases of pancreatic cancer in the 7MM nations was around 175,770 in 2021, and this was predicted to increase market growth during the historical period.
The upsurge of an unhealthy lifestyle and poor diet has heightened the number of individuals suffering from pancreatic diseases/conditions. The high incidence of diabetes patients has been mainly ascribed to the rising demand for packaged foods and beverages with elevated amounts of sugar, which also significantly contributes to the growing cases of pancreatic cancer patients. Thus, these factors will drive the market growth during the forecast period with a CAGR of 13.5%.
Which are Some Prominent Drivers of Pancreatic Cancer Market?
Owing to the lack of therapeutic procedures for early diagnosis, the pancreatic cancer market is expanding in developed nations
The American Society of Clinical Oncology predicts that 62,210 adults in the United States will be diagnosed with pancreatic cancer in 2022. The high prevalence of pancreatic cancer, which causes germline mutations, is also predicted to boost overall growth.
Besides that, the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to the body's healthy peripheral cells. The industry is being influenced by the increasing prevalence of pancreatic cancer and the requirement for targeted therapy.
NCI funded research projects to empower the market to grow
The National Cancer Institute has sponsored several research programs dedicated to developing treatments and medications for pancreatic cancer. The Pancreatic Cancer Cohort Consortium, Pancreatic Cancer Cancer Detection Consortium (PCDC), Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC), Pancreatic Cancer Microenvironment Network (PaCMEN), RAS Initiative, Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), and others are instances of financed projects.
These programs each have their mission and targets, and they each seek to find novel solutions to the ailment. The Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), for instance, is an intervention designed to quickly implement principal scientific discoveries into medical settings. The Pancreatic SPORE grants promote novel and diverse methods of prevention and treatment.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Pancreatic Cancer Market?
rising costs of drug development and treatment, along with strict regulatory guidelines to constrain market growth
The elevated cost of drug advancement and treatment may stifle future growth. During the projected timeframe, the market will also face obstacles from stringent government laws and regulations. Inventions and comprehensive authorization methods can assist in overcoming these challenges and propelling the global pancreatic cancer market forward.
Which Regional Market is the Most Profitable for Pancreatic Cancer Manufacturers?
In 2021, the North American pancreatic cancer market dominated the global market. This is because pancreatic cancer is more prevalent in North American countries, with the United States having the most cancer victims globally. As a consequence, North America possessed the leading revenue proportion in the pancreatic cancer treatment market in 2021. It is primarily owing to the upgraded healthcare system, widespread utilization of pancreatic treatment procedures, and a huge target citizenry. Furthermore, the increasing prevalence of pancreatic cancer is driving up requirements for treatment options.
The Asia-Pacific pancreatic cancer market is expected to be the most rapidly sprouting in the globe. Asia Pacific, as a result, hand, is projected to expand the fastest during the projected timeline. The existence of well-established clinics and critical care centers, as well as a massive population suffering from pancreatic cancer, would help the industry develop in the Asia Pacific region. Furthermore, with the increasing number of pancreatic cancer cases in Asia Pacific, pancreatic cancer diagnosis and treatment must abide by the same protocol as in Western nations.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Country-wise Analysis
Why Will United States Dominate Pancreatic Cancer Market in North America?
The rapid rise of pancreatic cancer patients and, increased investment in healthcare infrastructure propel the market
In North America, the United States of America leads the pancreatic cancer market. Based on the American Cancer Society's National Survey, approximately 3% of cancers in the United States were pancreatic by 2021. Moreover, pancreatic cancers account for 9% of all cancer deaths. The rising number of pancreatic cancer patients is accompanied by higher investment in medical infrastructure.
The simplification of regulatory approval processes has resulted in the safe and prompt approval of clinical drugs and treatments in the United States, contributing to the rising demand for pancreatic cancer treatment options in the country.
Which European Nation Will Emerge as Highest Share Holder?
Surging tobacco consumption levels will propel the market forward
Germany had the highest number of cases reported of pancreatic cancer in Europe in 2021, with 21,859 cases. Rising tobacco consumption rates and a boost in cigarette smokers are expected to boost the expansion of the pancreatic cancer market.
Furthermore, rising cancer prevalence, increased alcohol consumption, rising obesity rates, and increasing acceptance of various treatment options available are all forecasting overall growth in this country.
Country-wise Forecast CAGRs for the Pancreatic Cancer Industry
|
China |
12% |
|
U.S. |
13.7% |
|
Australia |
10% |
|
France |
11% |
Category-wise Insights
Which End-User Segment Will Hold the Largest Market Share?
Hospitals segment is dominant owing to the modern infrastructure
Based on end-user, the Hospital segment is the largest profit segment in the global pancreatic cancer therapeutics market, and this trend is expected to persist in the forecast years. The hospital segment is dominant owing to the quick influx of patients admitted to hospitals due to competent medical practitioners and the accessibility of multiple systems. In addition, hospitals have decent infrastructure and a wide network, which is cruising market growth. The hospital segment accounted for a 48% share of the market in 2022.
Which Treatment Type Segments Will lead the Industry Growth?
Surgery and radiology segments are expected to lead the industry
Because of the incidence of these methodologies, treatment-type segments such as surgery and radiology are likely to dominate the market throughout the forecast period.
The prominence of targeted drugs and unique biologic therapeutics can also be credited to this segment's supremacy. Furthermore, personalized treatment systems are assisting in the segment's advancement.
Start-ups operating in the Pancreatic Cancer Domain
- Biosense was established in 2008. Biosense is a medical engineering and development company that produces ground-breaking diagnostics. Rexahn announced a contract with BioSense in April 2019 to commercialize its pancreatic cancer treatment in Greater China.
- ElmediX was established in 2015 as a spin-off of the University of Antwerp with a single objective in mind: to produce a disruptive solution for (pancreatic) cancer and other life-threatening ailments. They produce oncothermia-based treatments for pancreatic cancer that minimize the likelihood of toxicity to healthy tissue.
Market Competition
Key players in the pancreatic cancer market are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics.
- In December 2022, scientists developed the world's first early pancreatic cancer screening test, which utilizes worms to discover tumors. The test, which was initiated in Japan this month, claims to be 100% precise in detecting cancer and can trace it in its early stages.
- As per Oncolytics Biotech® Inc., the FDA approved pelareorep in December 2022 in conjunction with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, the chemotherapeutic agent's drugs gemcitabine and nab-paclitaxel for the diagnosis of advanced or metastatic pancreatic ductal adenocarcinoma (TSX: ONC).
Report Scope
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 2,125.57 Million |
|
Projected Forecast Value (2033) |
US$ 7,541.09 Million |
|
Global Growth Rate (2023-2033) |
13.5% CAGR |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018-2022 |
|
Forecast Period |
2023-2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Pancreatic Cancer Industry Survey
By Treatment Type:
- Chemotherapy
- Immunotherapy
- Hormone Therapy
- Surgery
- Radiation Therapy
- Targeted Drug Therapy
- Others
By Cancer Type:
- Endocrine Pancreatic Cancer
- Exocrine Pancreatic Cancer
By End User:
- Hospitals
- Clinics
- Diagnostic Laboratories
- Research Institutes
- Research Laboratories
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Frequently Asked Questions
As of 2022, the Pancreatic Cancer market was worth US$ 73.75 Million
Fact.MR foresees Pancreatic Cancer demand to reach US$ 2125.57 Million in 2023
From 2023-2033, Fact.MR expects Pancreatic Cancer revenue to flourish at a 13.5% CAGR
In 2033, Pancreatic Cancer market worth is poised to reach US$ 7541.09 Million
North American regional market is expected to rise 1.4X by 2033.
U.S. is expected to possess 35% market share for Pancreatic Cancer in 2033.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment Type, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment Type, 2023-2033
5.3.1. Chemotherapy
5.3.2. Immunotherapy
5.3.3. Hormone Therapy
5.3.4. Surgery
5.3.5. Radiation Therapy
5.3.6. Targeted Drug Therapy
5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018-2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Cancer Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Cancer Type, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Cancer Type, 2023-2033
6.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018-2022
6.5. Absolute $ Opportunity Analysis By Cancer Type, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End User , 2018-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User , 2023-2033
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Diagnostic Laboratories
7.3.4. Research Institutes
7.3.5. Research Laboratories
7.3.6. Others
7.4. Y-o-Y Growth Trend Analysis By End User , 2018-2022
7.5. Absolute $ Opportunity Analysis By End User , 2023-2033
8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Treatment Type
9.2.3. By Cancer Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By Cancer Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment Type
10.2.3. By Cancer Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Cancer Type
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Treatment Type
11.2.3. By Cancer Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Cancer Type
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Treatment Type
12.2.3. By Cancer Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Cancer Type
12.3.4. By End User
12.4. Key Takeaways
13. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Treatment Type
13.2.3. By Cancer Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Cancer Type
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Treatment Type
14.1.2.2. By Cancer Type
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Treatment Type
14.2.2.2. By Cancer Type
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Treatment Type
14.3.2.2. By Cancer Type
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Treatment Type
14.4.2.2. By Cancer Type
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Treatment Type
14.5.2.2. By Cancer Type
14.5.2.3. By End User
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Treatment Type
14.6.2.2. By Cancer Type
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Treatment Type
14.7.2.2. By Cancer Type
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Treatment Type
14.8.2.2. By Cancer Type
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Treatment Type
14.9.2.2. By Cancer Type
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Treatment Type
14.10.2.2. By Cancer Type
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Treatment Type
14.11.2.2. By Cancer Type
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Treatment Type
14.12.2.2. By Cancer Type
14.12.2.3. By End User
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Treatment Type
14.13.2.2. By Cancer Type
14.13.2.3. By End User
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Treatment Type
14.14.2.2. By Cancer Type
14.14.2.3. By End User
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Treatment Type
14.15.2.2. By Cancer Type
14.15.2.3. By End User
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Treatment Type
14.16.2.2. By Cancer Type
14.16.2.3. By End User
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Treatment Type
14.17.2.2. By Cancer Type
14.17.2.3. By End User
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Treatment Type
14.18.2.2. By Cancer Type
14.18.2.3. By End User
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Treatment Type
14.19.2.2. By Cancer Type
14.19.2.3. By End User
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Treatment Type
14.20.2.2. By Cancer Type
14.20.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Treatment Type
15.3.3. By Cancer Type
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Pfizer Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Novartis AG
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Eli Lilly and Company
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Bristol Myers Squibb Company
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Zydus Cadila
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. AstraZeneca PLC
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Myriad Genetics Inc.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. F Hoffmann-La Roche Ltd.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. PharmaCyte Biotech Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Teva Pharmaceutical Industries Ltd.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033
Table 4: Global Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 5: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 6: North America Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 7: North America Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033
Table 8: North America Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 10: Latin America Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 11: Latin America Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033
Table 12: Latin America Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 14: Europe Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 15: Europe Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033
Table 16: Europe Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033
Table 20: Asia Pacific Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 22: MEA Market Value (US$ Mn) Forecast by Treatment Type, 2018-2033
Table 23: MEA Market Value (US$ Mn) Forecast by Cancer Type, 2018-2033
Table 24: MEA Market Value (US$ Mn) Forecast by End User , 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Cancer Type, 2023-2033
Figure 3: Global Market Value (US$ Mn) by End User , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 8: Global Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 11: Global Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033
Figure 14: Global Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 17: Global Market Attractiveness by Treatment Type, 2023-2033
Figure 18: Global Market Attractiveness by Cancer Type, 2023-2033
Figure 19: Global Market Attractiveness by End User , 2023-2033
Figure 20: Global Market Attractiveness by Region, 2023-2033
Figure 21: North America Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 22: North America Market Value (US$ Mn) by Cancer Type, 2023-2033
Figure 23: North America Market Value (US$ Mn) by End User , 2023-2033
Figure 24: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 28: North America Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 31: North America Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033
Figure 34: North America Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 37: North America Market Attractiveness by Treatment Type, 2023-2033
Figure 38: North America Market Attractiveness by Cancer Type, 2023-2033
Figure 39: North America Market Attractiveness by End User , 2023-2033
Figure 40: North America Market Attractiveness by Country, 2023-2033
Figure 41: Latin America Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 42: Latin America Market Value (US$ Mn) by Cancer Type, 2023-2033
Figure 43: Latin America Market Value (US$ Mn) by End User , 2023-2033
Figure 44: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 48: Latin America Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 51: Latin America Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033
Figure 54: Latin America Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 57: Latin America Market Attractiveness by Treatment Type, 2023-2033
Figure 58: Latin America Market Attractiveness by Cancer Type, 2023-2033
Figure 59: Latin America Market Attractiveness by End User , 2023-2033
Figure 60: Latin America Market Attractiveness by Country, 2023-2033
Figure 61: Europe Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 62: Europe Market Value (US$ Mn) by Cancer Type, 2023-2033
Figure 63: Europe Market Value (US$ Mn) by End User , 2023-2033
Figure 64: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 68: Europe Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 71: Europe Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033
Figure 74: Europe Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 77: Europe Market Attractiveness by Treatment Type, 2023-2033
Figure 78: Europe Market Attractiveness by Cancer Type, 2023-2033
Figure 79: Europe Market Attractiveness by End User , 2023-2033
Figure 80: Europe Market Attractiveness by Country, 2023-2033
Figure 81: Asia Pacific Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 82: Asia Pacific Market Value (US$ Mn) by Cancer Type, 2023-2033
Figure 83: Asia Pacific Market Value (US$ Mn) by End User , 2023-2033
Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033
Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033
Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023-2033
Figure 98: Asia Pacific Market Attractiveness by Cancer Type, 2023-2033
Figure 99: Asia Pacific Market Attractiveness by End User , 2023-2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023-2033
Figure 101: MEA Market Value (US$ Mn) by Treatment Type, 2023-2033
Figure 102: MEA Market Value (US$ Mn) by Cancer Type, 2023-2033
Figure 103: MEA Market Value (US$ Mn) by End User , 2023-2033
Figure 104: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 108: MEA Market Value (US$ Mn) Analysis by Treatment Type, 2018-2033
Figure 109: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023-2033
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023-2033
Figure 111: MEA Market Value (US$ Mn) Analysis by Cancer Type, 2018-2033
Figure 112: MEA Market Value Share (%) and BPS Analysis by Cancer Type, 2023-2033
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Cancer Type, 2023-2033
Figure 114: MEA Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 115: MEA Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 116: MEA Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 117: MEA Market Attractiveness by Treatment Type, 2023-2033
Figure 118: MEA Market Attractiveness by Cancer Type, 2023-2033
Figure 119: MEA Market Attractiveness by End User , 2023-2033
Figure 120: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
